Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong (China) *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

HTRF Human Total CDK6 Detection Kit, 500 Assay Points

The Total CDK6 kit is designed to monitor the expression level of cellular CDK6 (Cyclin-Dependent Kinase 6).

View product information

Feature	Specification
Application	細胞シグナル伝達
Sample Volume	16 µL

The Total CDK6 kit is designed to monitor the expression level of cellular CDK6 (Cyclin-Dependent Kinase 6).

View product information

Product variants

Unit Size: 500 assay points

Part #:

64CDK6TPEG

Unit Size: 10,000 assay points

Part #:

64CDK6TPEH

Unit Size: 50,000 assay points

Part #:

64CDK6TPEY

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption, and disposal requirements under European REACH regulations (EC 1907/2006).

Request more information

Product information

Overview

The Total CDK6 cellular assay monitors CDK6 protein levels.

CDK6 (Cyclin-Dependent Kinase 6) is a member of the subfamily of CDKs that coordinate cell cycle progression in mammalian cells (also including CDK1, CDK2, and CDK4). In the early G1 phase of the cell cycle, CDK6 is activated by interaction with Cyclin D and mono-phosphorylates the tumor suppressor RB (protein of retinoblastoma), leading to the transcription of genes required for G1/S phase transition.

Dysregulated activation of CDK6, leading to uncontrolled cell division, is a hallmark of cancers. Inhibition of CDK6 is thus an active research area, especially since the emergence of new approaches involving PROTACs (PROteolysis TArgeting Chimeras).

How it works

Total CDK6 assay principle

The Total CDK6 assay quantifies the expression level of CDK6 in a cell lysate. Unlike Western Blot, the assay is entirely plate-based and does not require gels, electrophoresis, or transfer. The Total CDK6 assay uses two labeled antibodies, one coupled to a donor fluorophore and the other to an acceptor. Both antibodies are highly specific for a distinct epitope on the protein. In the presence of CDK6 in a cell extract, the addition of these conjugates brings the donor fluorophore into close proximity with the acceptor and thereby generates a FRET signal. Its intensity is directly proportional to the concentration of the protein present in the sample, and provides a means of assessing the protein's expression under a no-wash assay format.

Total CDK6 two-plate assay protocol

The two-plate protocol involves culturing cells in a 96-well plate before lysis, then transferring lysates to a 384-well low volume detection plate before the addition of Total CDK6 HTRF detection reagents. This protocol enables the cells' viability and confluence to be monitored.

Total CDK6 one-plate assay protocol

Detection of Total CDK6 with HTRF reagents can be performed in a single plate used for culturing, stimulation, and lysis. No washing steps are required. This HTS designed protocol enables miniaturization while maintaining robust HTRF quality.

Assay validation

Validation of the specificity of Total CDK2, Total CDK4, and Total CDK6 assays by siRNA experiments

HeLa and HEK293 cells were plated in 96-well plates (40,000 and 50,000 cells/well respectively) and cultured for 24h. The cells were then transfected with siRNAs specific for CDK1, CDK2, CDK4, or CDK6, as well as with a negative control siRNA. After 48h incubation, the cells were lyzed and 16 µL of lysates were transferred into a 384-well low volume white microplate before the addition of 4 µL of the HTRF Total CDK2, Total CDK4, or Total CDK6 detection antibodies. The HTRF signal was recorded after an overnight incubation.

Cell transfection with each specific CDK2, CDK4, or CDK6 siRNA led to a 77 to 97% signal decrease compared to the cells transfected with the negative siRNA. It should be noted that the small signal decrease observed on the total CDK6 assay when cells were transfected with CDK2 siRNA was expected, since CDK2 knockdown leads to down-regulation of CDK6 (Bačević et al., Sci Rep. 2017; 7: 13429). Taken together, these data demonstrate that HTRF Total CDK2, Total CDK4, and Total CDK6 assays are specific for each kinase and do not cross-react with other cell cycle CDK family members.

Validation of total CDK2 assay specificity by siRNA experiments

Validation of total CDK4 assay specificity by siRNA experiments

Assessment of total CDK6 levels in HeLa and HEK293 cell lines

The human cell lines HeLa and HEK293 were cultured in T175 flasks for 48h and then lysed with 3 mL of supplemented lysis buffer #1 (1X). Serial dilutions of each cell lysate were analyzed for their total CDK6 content by transferring 16 µL of samples into a 384-well low volume white microplate and adding 4 µL of the HTRF Total CDK6 detection antibodies. The HTRF signal was recorded after an overnight incubation.

HTRF total CDK6 assay compared to Western Blot

HEK293 cells were cultured in a T175 flask in complete culture medium at 37°C-5% CO2. After 48h incubation, the cells were lysed with 3 mL of supplemented lysis buffer #1 (1X) for 30 minutes at RT under gentle shaking.

Serial dilutions of the cell lysate were performed using supplemented lysis buffer, and 16 µL of each dilution were transferred into a low volume white microplate before the addition of 4 µL of HTRF total CDK6 detection reagents. Equal amounts of lysates were used for a side by side comparison between HTRF and Western Blot.

Using the HTRF total CDK6 assay, 800 cells/well were enough to detect a significant signal, while 1,600 cells were needed to obtain a minimal chemiluminescent signal using Western Blot. Therefore in these conditions, the HTRF total CDK6 assay was twice as sensitive as the Western Blot technique.

Simplified pathway

Role of CDK6 in the cell-division cycle

CDK6 (Cyclin-Dependent Kinase 6) is a member of the subfamily of CDKs that coordinate cell cycle progression in mammalian cells (also including CDK1, CDK2, and CDK4).

Mitogenic signals, such as growth factors, trigger cells to enter the G1 phase of the cell cycle by inducing cyclin D synthesis. Cyclin D then interacts with CDK4 and CDK6 to form active complexes. Both activated kinases are then able to mono-phosphorylate the tumor suppressor RB (protein of retinoblastoma), which still binds to transcription factor E2F, but some genes can be transcribed, such as cyclin E. In the late G1 and early S phases, Cyclin E interacts with and activates CDK2, which in turn phosphorylates additional sites on RB resulting in its complete inactivation. The E2F-responsive genes required for S phase progression are thus induced, such as Cyclin A which then interacts with CDK2 to form Cyclin A/CDK2 complexes. CDK2 finally phosphorylates Cdc25B & Cdc25C phosphatases, which in turn activate CDK1, required for progression in the G2 and M phases of the cell-division cycle.

Specifications

Other specifications

Application	Cell Signaling
Brand	HTRF
Detection Modality	HTRF
Lysis Buffer Compatibility	Lysis Buffer 1 Lysis Buffer 4 Lysis Buffer 5
Molecular Modification	Total
Product Group	Kit
Sample Volume	16 µL
Shipping Conditions	Shipped in Dry Ice
Target Class	Phosphoproteins
Target Species	Human
Technology	TR-FRET
Therapeutic Area	Oncology & Inflammation
Unit Size	500 assay points